Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety and dose-finding trial of sevuparin in children with severe malaria
PACTR202007890194806Phase 1Recruiting
- Sponsor
- Imperial College London
- Start
- Jul 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 1 trial of sevuparin in malaria (2 arms), sponsored by Imperial College London. Primary endpoint: Activated partial thromboplastin time safety endpoint. Started Jul 2020; status: recruiting.
02
Drugs
sevuparin
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202007890194806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007890194806.